To see this page, please, enable javaScript and styleSheets on your browser: Tools -> Internet Options ...
Reload !
Gene C19orf48andSNORD88CandSNORD88BTABLE OF CONTENTS / OPEN CLOSE ALL PARAGRAPHS
Summary back to top
Compact gene diagram back to top
398 supporting clones for gene C19orf48andSNORD88CandSNORD88B back to top
cDNA accession
Links to the sequence
Tissue

most 5' clones
in red
Match
mRNA
From bp
to bp
in mRNA
From bp
to bp
in accs.
Clone encodes
complete protein
(with AA variation)
Features Anomalies
detected by
AceView
Accession
match over
(% length)
Base differences
relative to genome
(% identity)
BM561531 duodenal adenocarcinoma, cell line, small intestine .a 1 to 941 1 to 952 exact tiling clone,   952/952
(100 %)
18 diff
(98.2 %id)
BX390926   .b 1 to 892 1 to 881 G7S T15L I16* tiling clone,   881/881
(100 %)
20 diff
(97.8 %id)
DR762491 embryonic stem .b 77 to 832 1 to 756   tiling clone,   756/756
(100 %)
6 diff
(99.3 %id)
BE792844 lung, small cell carcinoma .b 85 to 847 1 to 763   tiling clone,   763/763
(100 %)
2 diff
(99.8 %id)
BG339927 leiomyosarcoma cell line, uterus .b 87 to 803 1 to 708   tiling clone,   708/891
(79 %)
13 diff
(98.6 %id)
BI253484 cervical carcinoma cell line, cervix .b 87 to 904 1 to 817   tiling clone,   817/823
(99 %)
17 diff
(98.0 %id)
BX283891 carcinoma, cell line, Prostate .c 1 to 514 1 to 514 exact tiling clone,   514/514
(100 %)
2 diff
(99.7 %id)
BG332995 large cell carcinoma, lung .c 29 to 911 1 to 879   tiling clone,   879/882
(99 %)
30 diff
(96.6 %id)
BI091298 cervix .c 30 to 690 1 to 662       662/664
(99 %)
2 diff
(99.7 %id)
BQ229486 melanotic melanoma, skin .c 32 to 869 12 to 858   tiling clone,   847/858
(98 %)
10 diff
(98.9 %id)
CV808322 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .c 33 to 658 1 to 627       627/779
(80 %)
22 diff
(97.2 %id)
CN367054 embryonic stem cells, DMSO-treated H9 cellline .c 37 to 601 1 to 565       566/565
(100 %)
6 diff
(99.0 %id)
BM014871 breast, mammary adenocarcinoma, cell line .c 37 to 855 1 to 819   tiling clone,   819/819
(100 %)
5 diff
(99.4 %id)
TI_59392950   .c 37 to 855 81 to 899       819/819
(100 %)
5 diff
(99.4 %id)
CX866095 embryonic stem .c 38 to 730 1 to 693       693/693
(100 %)
0 diff
(100 %id)
H08654 whole brain .c 50 to 429 1 to 384       384/386
(99 %)
11 diff
(97.2 %id)
BE254863 eye, retinoblastoma .c 50 to 545 1 to 496       496/496
(100 %)
0 diff
(100 %id)
BM553207 brain, medulla .d 1 to 976 17 to 1004 exact tiling clone,   988/1118
(88 %)
50 diff
(95.6 %id)
CV815774 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .d 7 to 839 1 to 836       836/879
(95 %)
24 diff
(97.3 %id)
BG739775 skin .d 39 to 611 5 to 589       590/869
(67 %)
29 diff
(96.7 %id)
TI_154179258   .d 43 to 874 71 to 901       831/833
(99 %)
18 diff
(97.9 %id)
TI_154179264   .d 43 to 879 72 to 898       827/842
(98 %)
24 diff
(97.2 %id)
TI_154179328   .d 43 to 781 70 to 809       740/828
(89 %)
20 diff
(97.6 %id)
CR623478 Placenta Cot 25-normalized .d 46 to 1684 1 to 1639   tiling clone,   1639/1639
(100 %)
0 diff
(100 %id)
BX381642 Placenta Cot 25-normalized .d 46 to 864 1 to 821   fully sequenced,   821/821
(100 %)
5 diff
(99.4 %id)
BM552719 brain, medulla .d 46 to 911 32 to 910       879/1153
(76 %)
56 diff
(95.2 %id)
CF146742 CNCAP(3)T-225 cell line, Prostate .d 46 to 693 11 to 659       649/659
(98 %)
3 diff
(99.6 %id)
CF146747 CNCAP(3)T-225 cell line, Prostate .d 46 to 688 11 to 654       644/654
(98 %)
1 diff
(99.9 %id)
CF146803 CNCAP(3)T-225 cell line, Prostate .d 46 to 652 11 to 620       610/620
(98 %)
7 diff
(98.9 %id)
BF312637 brain, neuroblastoma .d 52 to 691 1 to 638       638/638
(100 %)
7 diff
(99.0 %id)
BI196572 brain, neuroblastoma .d 53 to 899 1 to 847       847/848
(99 %)
36 diff
(95.8 %id)
BE261955 brain, neuroblastoma .d 72 to 745 1 to 670       670/722
(92 %)
19 diff
(97.4 %id)
BE313102 brain, neuroblastoma .d 83 to 853 14 to 772       759/928
(81 %)
37 diff
(96.1 %id)
BQ071964 brain, neuroblastoma, cell line .d 107 to 690 1 to 587       587/1158
(50 %)
17 diff
(98.6 %id)
BG106396 lymph, lymphoma, cell line .d 142 to 898 1 to 768       768/795
(96 %)
20 diff
(97.5 %id)
BE254039 eye, retinoblastoma .d 300 to 1021 1 to 721       721/723
(99 %)
3 diff
(99.6 %id)
BG436762 large cell carcinoma, lung .d 304 to 1121 1 to 818       818/818
(100 %)
5 diff
(99.4 %id)
BF803833 colon_ins .d 322 to 634 321 to 11     Submitted on the opposite strand 311/323
(96 %)
0 diff
(100 %id)
AW370043 breast .d 452 to 1102 649 to 1       649/649
(100 %)
7 diff
(99.0 %id)
BX381641 Placenta Cot 25-normalized .d 845 to 1684 837 to 1   fully sequenced,   837/837
(100 %)
40 diff
(95.3 %id)
BM906506 ovary (pool of 3) .e 1 to 930 1 to 933 T44S tiling clone,   933/1019
(91 %)
31 diff
(97.0 %id)
CX757097 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .e 1 to 712 1 to 707 exact   Submitted on the opposite strand 707/750
(94 %)
13 diff
(98.3 %id)
TI_154182684   .e 3 to 743 74 to 805 exact     732/915
(80 %)
26 diff
(97.2 %id)
TI_154183251   .e 3 to 820 75 to 887 K8T L9A R10*     813/816
(99 %)
15 diff
(98.2 %id)
BG753258 eye, normal pigmented retinal epithelium .e 5 to 861 1 to 856   tiling clone,   856/856
(100 %)
12 diff
(98.6 %id)
BM458378 lymph, lymphoma, cell line .e 6 to 965 1 to 981   tiling clone,   981/1128
(86 %)
45 diff
(96.1 %id)
BQ054356 blood, natural killer cells, cell line .e 6 to 1004 1 to 1017   tiling clone,   1017/1053
(96 %)
33 diff
(96.9 %id)
BQ438891 large cell carcinoma, lung .e 6 to 864 1 to 872   tiling clone,   872/886
(98 %)
29 diff
(96.8 %id)
CR591122 T cells (Jurkat cell line) Cot10-normalized .f 1 to 1689 1 to 1689 exact tiling clone,   1689/1689
(100 %)
0 diff
(100 %id)
BX362144   .f 1 to 838 1 to 836 exact fully sequenced,   836/836
(100 %)
3 diff
(99.7 %id)
TI_45378866   .f 14 to 750 75 to 812 T43S     738/812
(90 %)
10 diff
(98.8 %id)
TI_154178813   .f 78 to 840 72 to 831 exact     760/871
(87 %)
14 diff
(98.4 %id)
TI_154172789   .f 213 to 787 78 to 665 exact     588/619
(94 %)
19 diff
(97.0 %id)
NM_199250.1   .f 215 to 1717 1 to 1503 exact RefSeq, AAA   1503/1503
(100 %)
0 diff
(100 %id)
BX394156 Neuroblastoma Cot 25-normalized .f 264 to 1369 1 to 1086 exact     1086/1098
(98 %)
42 diff
(96.2 %id)
BX400114   .f 276 to 1324 1 to 1036 T43S     1036/1070
(96 %)
29 diff
(97.3 %id)
W79632 heart .f 276 to 689 1 to 414 exact     414/414
(100 %)
4 diff
(99.1 %id)
CX785356 human embryonic stem cells .f 286 to 1105 1 to 820 exact     820/820
(100 %)
0 diff
(100 %id)
BG684509 B-cells, primary B-cells from tonsils (cell line) .f 305 to 1126 1 to 817 exact     817/818
(99 %)
9 diff
(98.9 %id)
BG758898 B-cells, primary B-cells from tonsils (cell line) .f 305 to 1313 1 to 1006 exact     1006/1049
(95 %)
39 diff
(96.3 %id)
TI_57244185   .f 309 to 1078 35 to 803 exact     769/803
(95 %)
13 diff
(98.4 %id)
F12078 brain, total brain .f 315 to 686 1 to 372 P47L     372/372
(100 %)
2 diff
(99.5 %id)
ES310713 scalp interfollicular dermis, skin .f 316 to 881 1 to 568 T43S     568/570
(99 %)
7 diff
(98.8 %id)
AA314757 colon .f 321 to 753 1 to 433 exact     433/441
(98 %)
1 diff
(99.8 %id)
BP237017 coronary artery .f 336 to 917 1 to 582 exact     582/582
(100 %)
0 diff
(100 %id)
CV805992 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .f 338 to 1072 25 to 757 exact     733/758
(96 %)
8 diff
(99.0 %id)
BM465197 eye, retinoblastoma .f 340 to 1212 31 to 907 exact     877/909
(96 %)
19 diff
(98.0 %id)
BG420705 Kidney, renal cell adenocarcinoma .f 341 to 1121 1 to 771 exact     771/911
(84 %)
16 diff
(98.3 %id)
BG773752 choriocarcinoma, placenta .f 341 to 1008 1 to 668 exact     668/671
(99 %)
1 diff
(99.9 %id)
CX786479 human embryonic stem cells .f 343 to 1116 1 to 774 exact     774/774
(100 %)
0 diff
(100 %id)
BG472664 eye, retinoblastoma .f 345 to 1186 1 to 846 exact     846/849
(99 %)
39 diff
(95.5 %id)
BG328956 eye, retinoblastoma .f 346 to 1122 1 to 772 exact     772/946
(81 %)
24 diff
(97.5 %id)
BG396314 eye, retinoblastoma .f 346 to 1122 1 to 771 exact     771/900
(85 %)
13 diff
(98.6 %id)
BG697238 skin .f 346 to 1121 1 to 776 exact     776/776
(100 %)
1 diff
(99.9 %id)
BI755421 brain .f 346 to 1123 1 to 781 exact     781/781
(100 %)
3 diff
(99.7 %id)
TI_154162585   .f 346 to 972 77 to 694 exact     618/1061
(58 %)
16 diff
(98.5 %id)
TI_151789395   .f 346 to 1176 76 to 903 R9*     828/944
(87 %)
28 diff
(97.1 %id)
EC475821 Prostate .f 347 to 442 1 to 95       95/95
(100 %)
3 diff
(96.9 %id)
BG481799 choriocarcinoma, placenta .f 347 to 1216 1 to 866 exact     866/924
(93 %)
21 diff
(97.8 %id)
BG823709 adenocarcinoma cell line, colon .f 347 to 1263 1 to 913 exact     913/913
(100 %)
39 diff
(95.8 %id)
BG824965 muscle, rhabdomyosarcoma .f 347 to 1236 1 to 890 exact     890/890
(100 %)
24 diff
(97.4 %id)
BI114300 muscle, rhabdomyosarcoma .f 347 to 1317 1 to 965 exact     965/970
(99 %)
61 diff
(93.8 %id)
BM466429 eye, retinoblastoma .f 347 to 1213 1 to 889 exact     889/1053
(84 %)
29 diff
(97.3 %id)
BQ072356 pooled lung and spleen .f 347 to 1330 1 to 988 exact     988/990
(99 %)
20 diff
(98.0 %id)
BQ648709 hepatocellular carcinoma, cell line, Liver .f 347 to 1267 1 to 930 T43S     930/984
(94 %)
37 diff
(96.3 %id)
CN367049 embryonic stem cells, DMSO-treated H9 cellline .f 348 to 921 1 to 574 exact     574/574
(100 %)
0 diff
(100 %id)
BG481615 choriocarcinoma, placenta .f 348 to 1160 1 to 812 exact     812/953
(85 %)
18 diff
(98.2 %id)
TI_59384804   .f 348 to 917 123 to 691 H24Q     569/569
(100 %)
3 diff
(99.5 %id)
TI_154177468   .f 348 to 816 77 to 536 exact     460/568
(80 %)
11 diff
(98.1 %id)
BM910651 astrocytoma grade IV, cell line, brain .f 349 to 1213 1 to 870 exact     870/1089
(79 %)
9 diff
(99.2 %id)
BM809573 amelanotic melanoma, cell line, skin .f 349 to 1394 1 to 1058 exact     1058/1126
(93 %)
71 diff
(93.7 %id)
BM456401 lymph, lymphoma, cell line .f 349 to 1153 1 to 814 exact     814/834
(97 %)
11 diff
(98.7 %id)
BM547408 ovary (pool of 3) .f 349 to 1394 1 to 1060 T43S     1060/1080
(98 %)
45 diff
(95.9 %id)
BM906786 ovary (pool of 3) .f 349 to 1361 13 to 1033 T43S     1021/1037
(98 %)
37 diff
(96.5 %id)
BQ953000 carcinoma, cell line, Prostate .f 349 to 1153 1 to 819 exact     819/1103
(74 %)
28 diff
(97.5 %id)
BU849536 ovary, teratocarcinoma, cell line .f 349 to 1160 1 to 816 exact     816/859
(94 %)
10 diff
(98.9 %id)
BE281032 choriocarcinoma, placenta .f 350 to 1028 16 to 694 exact     679/695
(97 %)
1 diff
(99.9 %id)
BM546337 ovary (pool of 3) .f 351 to 1348 24 to 1030 T43S     1007/1104
(91 %)
29 diff
(97.4 %id)
BQ652179 hepatocellular carcinoma, cell line, Liver .f 351 to 1117 18 to 792 exact     775/968
(80 %)
14 diff
(98.6 %id)
BF311515 brain, neuroblastoma .f 353 to 1127 1 to 776       776/851
(91 %)
17 diff
(98.1 %id)
BG332976 large cell carcinoma, lung .f 353 to 1250 1 to 896       896/899
(99 %)
26 diff
(97.2 %id)
BG826297 muscle, rhabdomyosarcoma .f 353 to 1177 1 to 830       830/840
(98 %)
35 diff
(95.9 %id)
BM018761 astrocytoma grade IV, cell line, brain .f 353 to 1233 1 to 891       891/893
(99 %)
17 diff
(98.1 %id)
BM019096 astrocytoma grade IV, cell line, brain .f 353 to 1156 1 to 813       813/813
(100 %)
25 diff
(97.0 %id)
BM020455 astrocytoma grade IV, cell line, brain .f 353 to 1236 1 to 880       880/880
(100 %)
16 diff
(98.2 %id)
TI_59384629   .f 353 to 775 495 to 922       430/861
(49 %)
25 diff
(97.1 %id)
TI_59381480   .f 353 to 1102 101 to 855       755/935
(80 %)
19 diff
(98.0 %id)
TI_59391798   .f 353 to 1197 83 to 929       847/847
(100 %)
6 diff
(99.3 %id)
TI_59389430   .f 353 to 1233 99 to 989       891/893
(99 %)
17 diff
(98.1 %id)
TI_59389776   .f 353 to 1156 94 to 906       813/813
(100 %)
25 diff
(97.0 %id)
TI_59391242   .f 353 to 1236 101 to 980       880/880
(100 %)
16 diff
(98.2 %id)
TI_154178312   .f 353 to 895 81 to 622       542/543
(99 %)
11 diff
(98.0 %id)
TI_154179205   .f 353 to 1237 70 to 947       878/878
(100 %)
19 diff
(97.9 %id)
BC037227 Placenta, choriocarcinoma .f 354 to 1717 1 to 1364   available from MGC, AAA   1364/1364
(100 %)
0 diff
(100 %id)
CN367055 embryonic stem cells, DMSO-treated H9 cellline .f 354 to 1013 1 to 660       660/660
(100 %)
0 diff
(100 %id)
CN367057 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .f 354 to 947 1 to 594       594/594
(100 %)
0 diff
(100 %id)
BF795279 lymph, lymphoma, cell line .f 354 to 1153 1 to 800       800/1176
(68 %)
18 diff
(98.5 %id)
BI222852 cervical carcinoma cell line, cervix .f 354 to 1160 1 to 809       809/825
(98 %)
31 diff
(96.3 %id)
BI770827 pooled lung and spleen .f 354 to 1185 1 to 829       829/830
(99 %)
21 diff
(97.5 %id)
BM013860 breast, mammary adenocarcinoma, cell line .f 354 to 1197 1 to 846       846/846
(100 %)
6 diff
(99.3 %id)
BM564858 eye, retinoblastoma .f 354 to 1208 1 to 865       865/972
(88 %)
12 diff
(98.8 %id)
CX164352 human embryonic stem cells differentiated toan early endodermal cell type .f 354 to 1120 1 to 767       767/767
(100 %)
0 diff
(100 %id)
CX870870 embryonic stem .f 354 to 1117 1 to 764       764/764
(100 %)
0 diff
(100 %id)
CX787905 human embryonic stem cells .f 354 to 1120 1 to 767       767/767
(100 %)
0 diff
(100 %id)
CX871481 embryonic stem .f 354 to 1131 1 to 778       778/778
(100 %)
0 diff
(100 %id)
DR761048 embryonic stem .f 354 to 1117 1 to 764       764/764
(100 %)
0 diff
(100 %id)
BM904956 melanotic melanoma, skin .f 355 to 1310 1 to 974       974/1014
(96 %)
30 diff
(97.1 %id)
CK904166 Islets of Langerhans, Pancreas .f 355 to 737 1 to 383       383/383
(100 %)
6 diff
(98.5 %id)
BU164440 large cell carcinoma, lung .f 355 to 1209 1 to 866       866/879
(98 %)
15 diff
(98.3 %id)
BQ423484 embryonal carcinoma, cell line, testis .f 355 to 1200 1 to 861       861/940
(91 %)
44 diff
(95.4 %id)
BU177142 melanotic melanoma, skin .f 355 to 1167 1 to 819       819/835
(98 %)
12 diff
(98.6 %id)
TI_154162673   .f 355 to 1023 78 to 743       666/1079
(61 %)
13 diff
(98.8 %id)
TI_154163117   .f 355 to 1071 81 to 797       717/717
(100 %)
16 diff
(97.8 %id)
TI_154179044   .f 355 to 1211 73 to 911       839/913
(91 %)
25 diff
(97.3 %id)
TI_154179649   .f 355 to 1195 72 to 905       834/835
(99 %)
26 diff
(96.9 %id)
TI_154179832   .f 355 to 1113 73 to 825       753/886
(84 %)
11 diff
(98.8 %id)
BG678358 skin, squamous cell carcinoma .f 356 to 1212 1 to 855       855/855
(100 %)
21 diff
(97.6 %id)
CB594358 Blood, promyelocytic leukemia .f 356 to 1123 1 to 778       778/894
(87 %)
14 diff
(98.5 %id)
TI_154163106   .f 356 to 1067 80 to 784       705/705
(100 %)
21 diff
(97.1 %id)
TI_154169179   .f 356 to 862 80 to 586       507/507
(100 %)
1 diff
(99.9 %id)
AI547282 Prostate .f 358 to 1212 10 to 852       843/948
(88 %)
36 diff
(96.3 %id)
CD634254   .f 358 to 1194 848 to 10       839/870
(96 %)
8 diff
(99.1 %id)
CR601120 HeLa cells Cot 25-normalized .f 358 to 1416 1 to 1059       1059/1059
(100 %)
0 diff
(100 %id)
CR604560 B cells (Ramos cell line) Cot 25-normalized .f 358 to 1695 1 to 1338       1338/1338
(100 %)
0 diff
(100 %id)
CR611148 Neuroblastoma Cot 25-normalized .f 358 to 1633 1 to 1276       1276/1276
(100 %)
0 diff
(100 %id)
CR611743 Neuroblastoma Cot 10-normalized .f 358 to 1517 1 to 1160       1160/1160
(100 %)
0 diff
(100 %id)
CR614468 fetal liver .f 358 to 1688 1 to 1331       1331/1331
(100 %)
0 diff
(100 %id)
CR615248 B cells (Ramos cell line) .f 358 to 1656 1 to 1299       1299/1299
(100 %)
0 diff
(100 %id)
CR615527 B cells (Ramos cell line) Cot 25-normalized .f 358 to 1692 1 to 1335       1335/1335
(100 %)
0 diff
(100 %id)
CR616224 Placenta Cot 25-normalized .f 358 to 1689 1 to 1332       1332/1332
(100 %)
0 diff
(100 %id)
CR625194 T cells (Jurkat cell line) Cot10-normalized .f 358 to 1668 1 to 1311       1311/1311
(100 %)
0 diff
(100 %id)
AL523972 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .f 358 to 1172 1 to 807   fully sequenced,   807/807
(100 %)
2 diff
(99.8 %id)
BX439426 placenta .f 358 to 1445 1 to 1083       1083/1120
(96 %)
23 diff
(98.0 %id)
BX362010   .f 358 to 1340 1 to 984       984/984
(100 %)
6 diff
(99.4 %id)
AL559240 T cells from T cell leukemia .f 358 to 1073 1 to 716   fully sequenced,   716/716
(100 %)
0 diff
(100 %id)
BX342335   .f 358 to 1298 1 to 942       942/942
(100 %)
2 diff
(99.8 %id)
BX365647   .f 358 to 1411 1 to 1059       1059/1063
(99 %)
11 diff
(99.0 %id)
BX363729   .f 358 to 1322 1 to 966       966/966
(100 %)
8 diff
(99.2 %id)
BX427362 fetal liver, Liver .f 358 to 878 1 to 522   fully sequenced,   522/522
(100 %)
1 diff
(99.9 %id)
CF134702 CNCAP(3)T-225 cell line, Prostate .f 358 to 922 8 to 572       566/572
(98 %)
6 diff
(99.0 %id)
CF141340 CNCAP(3)T-225 cell line, Prostate .f 358 to 818 8 to 468       462/468
(98 %)
6 diff
(98.8 %id)
BE409554 choriocarcinoma, placenta .f 358 to 1198 49 to 900       852/983
(86 %)
34 diff
(96.6 %id)
BQ058109 lymph, lymphoma, cell line .f 358 to 1323 29 to 1010       983/1085
(90 %)
27 diff
(97.6 %id)
BQ071691 brain, neuroblastoma, cell line .f 358 to 1179 30 to 867       838/1092
(76 %)
44 diff
(96.0 %id)
BU839647 hepatocellular carcinoma, cell line, Liver .f 358 to 1213 7 to 863       857/899
(95 %)
20 diff
(97.8 %id)
BQ880843 brain, neuroblastoma, cell line .f 358 to 1254 28 to 922       895/924
(96 %)
11 diff
(98.9 %id)
BU856200 ovary, teratocarcinoma, cell line .f 358 to 1248 10 to 906       897/906
(99 %)
17 diff
(98.2 %id)
CX754764 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .f 358 to 1076 7 to 725     Submitted on the opposite strand 719/725
(99 %)
6 diff
(99.2 %id)
CF145808 CNCAP(3)T-225 cell line, Prostate .f 358 to 952 8 to 602       596/602
(99 %)
6 diff
(99.1 %id)
CF146568 CNCAP(3)T-225 cell line, Prostate .f 358 to 980 11 to 633       623/633
(98 %)
0 diff
(100 %id)
CF147236 CNCAP(3)T-225 cell line, Prostate .f 358 to 985 11 to 638       628/638
(98 %)
0 diff
(100 %id)
CF147327 CNCAP(3)T-225 cell line, Prostate .f 358 to 987 8 to 637       631/637
(99 %)
6 diff
(99.1 %id)
CF123067 CNCAP(3)T-225 cell line, Prostate .f 358 to 986 11 to 638       628/638
(98 %)
1 diff
(99.9 %id)
TI_57216945   .f 358 to 1123 41 to 809       769/809
(95 %)
9 diff
(98.9 %id)
TI_57181952   .f 358 to 1185 39 to 863       826/864
(95 %)
27 diff
(96.9 %id)
TI_57181957   .f 358 to 1198 62 to 914       854/914
(93 %)
26 diff
(97.2 %id)
TI_154162774   .f 358 to 1256 80 to 972       893/1216
(73 %)
45 diff
(96.3 %id)
TI_154171352   .f 358 to 924 80 to 651       572/1085
(52 %)
11 diff
(99.0 %id)
TI_154172026   .f 358 to 958 80 to 681       602/602
(100 %)
9 diff
(98.6 %id)
TI_154178086   .f 358 to 1129 77 to 838       762/918
(83 %)
23 diff
(97.5 %id)
TI_154179923   .f 358 to 1182 73 to 886       814/928
(87 %)
18 diff
(98.1 %id)
TI_154179940   .f 358 to 1191 77 to 896       820/935
(87 %)
18 diff
(98.1 %id)
TI_154180012   .f 358 to 1057 77 to 774       698/953
(73 %)
8 diff
(99.2 %id)
TI_154181833   .f 358 to 1129 72 to 833       762/895
(85 %)
20 diff
(97.8 %id)
TI_154182830   .f 358 to 1113 72 to 819       748/887
(84 %)
20 diff
(97.8 %id)
BM698780 eye, fetal eyes .f 358 to 778 7 to 427       421/427
(98 %)
6 diff
(98.6 %id)
CN367064 embryonic stem cells, DMSO-treated H9 cellline .f 359 to 901 1 to 542       542/542
(100 %)
1 diff
(99.9 %id)
BG479673 choriocarcinoma, placenta .f 359 to 1285 1 to 917       917/920
(99 %)
35 diff
(96.2 %id)
BQ423644 melanotic melanoma, skin .f 359 to 1161 10 to 822       822/865
(95 %)
21 diff
(97.6 %id)
BQ423470 embryonal carcinoma, cell line, testis .f 359 to 1243 10 to 903       903/903
(100 %)
16 diff
(98.3 %id)
BU500483   .f 359 to 1213 10 to 867       867/895
(96 %)
12 diff
(98.7 %id)
BU507568 leiomyosarcoma, uterus .f 359 to 1196 10 to 847       847/885
(95 %)
8 diff
(99.1 %id)
CX165317 human embryonic stem cells differentiated toan early endodermal cell type .f 359 to 1118 10 to 769       769/769
(100 %)
1 diff
(99.9 %id)
TI_154172390   .f 359 to 945 79 to 665       589/589
(100 %)
0 diff
(100 %id)
BE313471 brain, neuroblastoma .f 361 to 816 1 to 456       456/456
(100 %)
0 diff
(100 %id)
BE900214 choriocarcinoma, placenta .f 361 to 1004 1 to 644       644/644
(100 %)
0 diff
(100 %id)
BQ213934 embryonal carcinoma, cell line, testis .f 361 to 1230 1 to 886       886/909
(97 %)
38 diff
(95.9 %id)
BE900901 choriocarcinoma, placenta .f 362 to 1156 1 to 786       786/850
(92 %)
21 diff
(97.6 %id)
TI_154181600   .f 363 to 1233 75 to 929       855/895
(95 %)
30 diff
(96.7 %id)
BE733372 choriocarcinoma, placenta .f 365 to 1130 1 to 759       759/759
(100 %)
9 diff
(98.9 %id)
BE900322 choriocarcinoma, placenta .f 365 to 1138 1 to 767       767/806
(95 %)
14 diff
(98.3 %id)
BE382514 brain, neuroblastoma .f 366 to 1000 1 to 635       635/635
(100 %)
0 diff
(100 %id)
BE794905 lung, small cell carcinoma .f 366 to 1152 1 to 790       790/792
(99 %)
6 diff
(99.3 %id)
BE280185 choriocarcinoma, placenta .f 367 to 986 1 to 618       618/618
(100 %)
2 diff
(99.7 %id)
BE407887 choriocarcinoma, placenta .f 367 to 1098 1 to 730       730/826
(88 %)
11 diff
(98.7 %id)
BE395544 endometrium, adenocarcinoma cell line, uterus .f 367 to 931 1 to 565       565/565
(100 %)
0 diff
(100 %id)
BQ054903 lymph, lymphoma, cell line .f 367 to 1201 1 to 846       846/1051
(80 %)
32 diff
(97.0 %id)
BQ642278 lymph, lymphoma, cell line .f 367 to 1208 1 to 847       847/895
(94 %)
15 diff
(98.4 %id)
BU508032 leiomyosarcoma, uterus .f 367 to 1487 1 to 1121       1121/1124
(99 %)
37 diff
(96.8 %id)
BE253947 eye, retinoblastoma .f 368 to 1182 1 to 809       809/870
(92 %)
20 diff
(97.8 %id)
BE251243 eye, retinoblastoma .f 368 to 807 1 to 440       440/440
(100 %)
0 diff
(100 %id)
BU189011 melanotic melanoma, skin .f 369 to 1229 1 to 870       870/871
(99 %)
16 diff
(98.2 %id)
BU931889 ovary, teratocarcinoma, cell line .f 370 to 1208 1 to 844       844/943
(89 %)
8 diff
(99.2 %id)
BM021473 Islets of Langerhans, Pancreas .f 371 to 921 1 to 551       551/551
(100 %)
0 diff
(100 %id)
BE264391 lung, small cell carcinoma .f 372 to 1010 1 to 638       638/639
(99 %)
2 diff
(99.7 %id)
DR762565 embryonic stem .f 372 to 1120 1 to 749       749/749
(100 %)
0 diff
(100 %id)
BM021984 Islets of Langerhans, Pancreas .f 373 to 874 1 to 501       501/501
(100 %)
2 diff
(99.7 %id)
CD519245 White Matter .f 373 to 1208 1 to 851       851/906
(93 %)
24 diff
(97.4 %id)
CN367053 embryonic stem cells, DMSO-treated H9 cellline .f 377 to 817 1 to 441       441/441
(100 %)
0 diff
(100 %id)
BG391653 embryonal carcinoma, cell line, testis .f 379 to 1222 1 to 842       842/1150
(73 %)
35 diff
(97.0 %id)
CN367059 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .f 380 to 1040 1 to 661       661/661
(100 %)
1 diff
(99.9 %id)
BE560512 Burkitt lymphoma, lymph .f 382 to 1211 1 to 817       817/860
(95 %)
29 diff
(96.7 %id)
CF144318 CNCAP(3)T-225 cell line, Prostate .f 394 to 790 1 to 396       395/396
(99 %)
4 diff
(99.0 %id)
CF144400 CNCAP(3)T-225 cell line, Prostate .f 394 to 907 1 to 513       512/513
(99 %)
3 diff
(99.5 %id)
CF144652 CNCAP(3)T-225 cell line, Prostate .f 394 to 504 1 to 110       109/110
(99 %)
4 diff
(96.4 %id)
CR590605 Neuroblastoma Cot 25-normalized .f 401 to 1657 1 to 1257       1257/1257
(100 %)
0 diff
(100 %id)
BX375691 Neuroblastoma Cot 25-normalized .f 401 to 1079 1 to 672   fully sequenced,   672/672
(100 %)
1 diff
(99.9 %id)
TI_154176327   .f 402 to 941 96 to 641       546/1194
(45 %)
14 diff
(98.9 %id)
TI_154176423   .f 402 to 1098 83 to 777       695/1012
(68 %)
18 diff
(98.3 %id)
TI_154176710   .f 402 to 972 81 to 651       571/574
(99 %)
18 diff
(96.9 %id)
TI_154176711   .f 402 to 971 81 to 651       571/573
(99 %)
40 diff
(93.1 %id)
TI_154176912   .f 402 to 936 80 to 614       535/535
(100 %)
3 diff
(99.5 %id)
TI_154176917   .f 402 to 935 80 to 613       534/534
(100 %)
4 diff
(99.3 %id)
TI_154141069   .f 407 to 890 80 to 581       502/505
(99 %)
29 diff
(94.3 %id)
BC006151 Eye, retinoblastoma .f 420 to 1717 1 to 1298   available from MGC, AAA   1298/1298
(100 %)
0 diff
(100 %id)
BE256672 eye, retinoblastoma .f 439 to 1015 1 to 577       577/577
(100 %)
0 diff
(100 %id)
CA916798 lung cancer .f 451 to 1708 1 to 1258       1258/1258
(100 %)
3 diff
(99.8 %id)
AY491972   .f 453 to 1714 1 to 1262       1262/1267
(99 %)
4 diff
(99.7 %id)
TI_154180283   .f 476 to 1286 101 to 907       807/833
(96 %)
14 diff
(98.4 %id)
CA488332   .f 479 to 1213 1 to 735       735/990
(74 %)
7 diff
(99.3 %id)
EC529137 Prostate .f 494 to 577 97 to 14       84/97
(86 %)
0 diff
(100 %id)
EC572894 Prostate .f 494 to 581 94 to 7       88/94
(93 %)
0 diff
(100 %id)
CR987272 T-Lymphocytes .f 494 to 989 1 to 496       496/497
(99 %)
1 diff
(99.8 %id)
T31430 colon, embryo .f 550 to 872 1 to 323       323/323
(100 %)
0 diff
(100 %id)
BM008649 adenocarcinoma, Pancreas .f 560 to 1474 1 to 922       922/922
(100 %)
27 diff
(97.1 %id)
TI_59386356   .f 561 to 1474 98 to 1018       921/921
(100 %)
26 diff
(97.2 %id)
TI_59384817   .f 561 to 1281 55 to 774       720/720
(100 %)
3 diff
(99.6 %id)
BM916537 amelanotic melanoma, cell line, skin .f 564 to 1395 1 to 836       836/1103
(75 %)
25 diff
(97.8 %id)
BQ055715 lymph, lymphoma, cell line .f 570 to 1336 1 to 775       775/1110
(69 %)
16 diff
(98.6 %id)
BX365646   .f 604 to 1676 1068 to 1       1068/1079
(98 %)
18 diff
(98.4 %id)
BM757071 Ascites, stomach .f 619 to 807 1 to 189       189/189
(100 %)
0 diff
(100 %id)
BM756947 Ascites, stomach .f 619 to 1118 1 to 500       500/500
(100 %)
0 diff
(100 %id)
BM784820 Ascites, stomach .f 619 to 984 1 to 366       366/366
(100 %)
0 diff
(100 %id)
BE888217 leiomyosarcoma, uterus .f 655 to 1201 1 to 547       547/547
(100 %)
0 diff
(100 %id)
EC497070 Prostate .f 688 to 783 96 to 1       96/96
(100 %)
0 diff
(100 %id)
TI_57180644   .f 688 to 1437 70 to 819       750/819
(91 %)
6 diff
(99.3 %id)
BX342334   .f 692 to 1675 983 to 1       983/983
(100 %)
7 diff
(99.3 %id)
BU933494 mixed (pool of 40 RNAs) .f 694 to 1492 1 to 823       823/824
(99 %)
38 diff
(95.4 %id)
BI860166 breast, mammary adenocarcinoma, cell line .f 700 to 1480 1 to 782       782/784
(99 %)
5 diff
(99.4 %id)
TI_57189995   .f 700 to 1480 54 to 835       782/784
(99 %)
5 diff
(99.4 %id)
EC494286 Prostate .f 709 to 799 91 to 1       91/91
(100 %)
0 diff
(100 %id)
EC494495 Prostate .f 709 to 799 91 to 1       91/91
(100 %)
0 diff
(100 %id)
EC494716 Prostate .f 709 to 799 91 to 1       91/91
(100 %)
0 diff
(100 %id)
EC511825 Prostate .f 709 to 797 95 to 5       91/95
(95 %)
0 diff
(100 %id)
EC537929 Prostate .f 709 to 799 91 to 1       91/91
(100 %)
0 diff
(100 %id)
EC552343 Prostate .f 709 to 799 91 to 1       91/91
(100 %)
0 diff
(100 %id)
EC566837 Prostate .f 709 to 799 91 to 1       91/91
(100 %)
0 diff
(100 %id)
EC581608 Prostate .f 709 to 799 91 to 1       91/91
(100 %)
0 diff
(100 %id)
EC581702 Prostate .f 709 to 799 91 to 1       91/91
(100 %)
0 diff
(100 %id)
CU444977 epidermis .f 721 to 1234 528 to 15     Submitted on the opposite strand 514/537
(95 %)
0 diff
(100 %id)
CU447439 epidermis .f 721 to 1234 10 to 523       514/537
(95 %)
2 diff
(99.7 %id)
CU452449 epidermis .f 721 to 1234 528 to 15     Submitted on the opposite strand 514/537
(95 %)
0 diff
(100 %id)
CU454800 epidermis .f 721 to 1234 10 to 523       514/537
(95 %)
2 diff
(99.7 %id)
EC552409 Prostate .f 722 to 809 1 to 88       88/88
(100 %)
0 diff
(100 %id)
BI334773 cervical carcinoma cell line, cervix .f 725 to 1548 1 to 825       825/826
(99 %)
2 diff
(99.8 %id)
TI_154144547   .f 730 to 1324 81 to 675       595/595
(100 %)
9 diff
(98.5 %id)
TI_57167317   .f 743 to 1479 32 to 775       744/776
(95 %)
17 diff
(97.9 %id)
EC568069 Prostate .f 789 to 886 97 to 1       97/97
(100 %)
4 diff
(95.9 %id)
TI_57164443   .f 802 to 1599 70 to 894       825/894
(92 %)
6 diff
(99.4 %id)
BX341003   .f 811 to 1689 878 to 1   fully sequenced,   878/878
(100 %)
6 diff
(99.4 %id)
BX427361 fetal liver, Liver .f 848 to 1688 840 to 1   fully sequenced,   840/840
(100 %)
15 diff
(98.3 %id)
BU184756 epithelioid carcinoma, Pancreas .f 861 to 1672 1 to 814       814/881
(92 %)
22 diff
(97.6 %id)
BX342933   .f 862 to 1718 1 to 856   fully sequenced,   856/856
(100 %)
5 diff
(99.5 %id)
CR610794 B cells (Ramos cell line) Cot 25-normalized .f 863 to 1718 1 to 856   tiling clone,   856/856
(100 %)
0 diff
(100 %id)
BX342932   .f 907 to 1700 789 to 1   fully sequenced,   789/789
(100 %)
14 diff
(98.3 %id)
EC580476 Prostate .f 930 to 1019 95 to 5       91/95
(95 %)
0 diff
(100 %id)
TI_151769573   .f 948 to 1569 103 to 723       621/778
(79 %)
22 diff
(97.2 %id)
TI_154192510   .f 997 to 1717 51 to 772   AAA   722/722
(100 %)
1 diff
(99.9 %id)
AL580895 T cells from T cell leukemia .f 1043 to 1668 627 to 1   fully sequenced,   627/627
(100 %)
1 diff
(99.9 %id)
BX375690 Neuroblastoma Cot 25-normalized .f 1049 to 1657 609 to 1   fully sequenced,   609/609
(100 %)
0 diff
(100 %id)
AL523971 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .f 1142 to 1632 485 to 1   fully sequenced,   485/485
(100 %)
5 diff
(99.0 %id)
W79488 heart .f 1243 to 1716 478 to 3       476/480
(99 %)
0 diff
(100 %id)
F09717 brain, total brain .f 1492 to 1717 226 to 1       226/228
(99 %)
0 diff
(100 %id)
BG385538 adenocarcinoma cell line, colon .g 1 to 672 1 to 668 T10S     668/677
(98 %)
7 diff
(99.0 %id)
BG823335 adenocarcinoma cell line, colon .g 1 to 948 1 to 959 exact tiling clone,   959/963
(99 %)
26 diff
(97.4 %id)
Z42736 brain, total brain .g 16 to 324 1 to 308       308/308
(100 %)
1 diff
(99.7 %id)
BE512868 adenocarcinoma cell line, colon .g 21 to 869 1 to 845   tiling clone,   845/936
(90 %)
36 diff
(96.2 %id)
F02213 brain, total brain .g 1032 to 1334 303 to 1   tiling clone,   303/303
(100 %)
0 diff
(100 %id)
BF981881 duodenal adenocarcinoma, cell line, small intestine .h 1 to 416 1 to 416 exact tiling clone,   416/417
(99 %)
1 diff
(99.8 %id)
BM843142 lymph node, stomach .i 1 to 508 1 to 508 exact     508/508
(100 %)
5 diff
(99.1 %id)
BQ947713 large cell carcinoma, lung .i 2 to 863 1 to 875 exact tiling clone,   875/968
(90 %)
27 diff
(97.3 %id)
BM760737 lymph node, stomach .i 2 to 724 1 to 723 exact tiling clone,   723/723
(100 %)
3 diff
(99.6 %id)
BM842772 lymph node, stomach .i 2 to 651 1 to 650 exact     650/650
(100 %)
4 diff
(99.4 %id)
BM843109 lymph node, stomach .i 2 to 604 1 to 603 exact     603/603
(100 %)
4 diff
(99.4 %id)
BM843201 lymph node, stomach .i 2 to 494 1 to 493 exact     493/493
(100 %)
3 diff
(99.4 %id)
BI258809 cervical carcinoma cell line, cervix .i 8 to 716 1 to 709 exact     709/709
(100 %)
1 diff
(99.9 %id)
BF312988 brain, neuroblastoma .i 9 to 742 1 to 735 exact     735/738
(99 %)
8 diff
(99.0 %id)
BF314723 brain, neuroblastoma .i 9 to 832 1 to 828 exact     828/985
(84 %)
30 diff
(97.0 %id)
BI253276 cervical carcinoma cell line, cervix .i 10 to 662 1 to 655 D22A H23P H24S S25L L26I ...     655/655
(100 %)
3 diff
(99.6 %id)
BM471092 leiomyosarcoma, uterus .i 11 to 800 1 to 799 exact     799/1118
(71 %)
21 diff
(98.2 %id)
BE798465 lung, small cell carcinoma .i 14 to 783 21 to 781       763/979
(77 %)
18 diff
(98.2 %id)
AA401866   .i 15 to 436 1 to 422       422/422
(100 %)
6 diff
(98.6 %id)
BM008761 adenocarcinoma, Pancreas .i 16 to 880 1 to 868   tiling clone,   868/869
(99 %)
18 diff
(98.0 %id)
TI_59386473   .i 17 to 880 61 to 927       867/868
(99 %)
14 diff
(98.4 %id)
TI_154177118   .i 17 to 555 81 to 619       539/540
(99 %)
4 diff
(99.3 %id)
TI_154177969   .i 17 to 797 66 to 843       778/928
(83 %)
19 diff
(98.0 %id)
TI_154178962   .i 18 to 861 70 to 904       835/914
(91 %)
21 diff
(97.8 %id)
BE742149 adenocarcinoma cell line, ovary .i 19 to 831 1 to 809       809/903
(89 %)
17 diff
(98.2 %id)
BE740211 adenocarcinoma cell line, ovary .i 19 to 745 1 to 721       721/999
(72 %)
10 diff
(99.0 %id)
CF145018 CNCAP(3)T-225 cell line, Prostate .i 20 to 536 11 to 527       517/527
(98 %)
2 diff
(99.7 %id)
CF145708 CNCAP(3)T-225 cell line, Prostate .i 20 to 672 11 to 664       654/664
(98 %)
1 diff
(99.9 %id)
CF146501 CNCAP(3)T-225 cell line, Prostate .i 20 to 669 10 to 660       652/660
(98 %)
6 diff
(99.1 %id)
BI253492 cervical carcinoma cell line, cervix .i 21 to 862 1 to 846   tiling clone,   846/847
(99 %)
26 diff
(97.0 %id)
BU194878 melanotic melanoma, skin .i 21 to 822 10 to 815       815/826
(98 %)
16 diff
(98.1 %id)
BE259913 brain, neuroblastoma .i 27 to 600 1 to 574       574/574
(100 %)
3 diff
(99.5 %id)
BE312822 brain, neuroblastoma .i 29 to 795 1 to 755       755/941
(80 %)
19 diff
(98.0 %id)
BG472166 eye, retinoblastoma .i 132 to 991 1 to 857   tiling clone,   857/857
(100 %)
11 diff
(98.8 %id)
DB234060 trachea .j 1 to 578 2 to 579 exact tiling clone, capped   578/578
(100 %)
0 diff
(100 %id)
BQ052527 blood, natural killer cells, cell line .j 8 to 458 1 to 456 exact     456/1162
(39 %)
14 diff
(98.8 %id)
CN277003 embryonic stem cells, DMSO-treated H9 cellline .j 81 to 255 1 to 175       175/175
(100 %)
1 diff
(99.5 %id)
BE144793 head_neck .k 1 to 264 269 to 5   tiling clone, Submitted on the opposite strand 265/269
(98 %)
0 diff
(100 %id)
BI260831 cervical carcinoma cell line, cervix .k 100 to 985 1 to 884 exact     884/897
(98 %)
41 diff
(95.5 %id)
BC051842 Cervix, carcinoma .k 103 to 1944 5 to 1846 exact tiling clone, available from MGC, AAA   1846/1846
(100 %)
3 diff
(99.9 %id)
NM_199249.1   .l 1 to 1666 1 to 1666 exact RefSeq, AAA   1666/1666
(100 %)
0 diff
(100 %id)
BX508552   .l 88 to 833 1 to 746   tiling clone,   746/746
(100 %)
6 diff
(99.2 %id)
BI260989 cervical carcinoma cell line, cervix .l 98 to 891 1 to 804       804/804
(100 %)
25 diff
(96.9 %id)
BM802982 duodenal adenocarcinoma, cell line, small intestine .l 103 to 1078 10 to 995   tiling clone,   986/1021
(96 %)
36 diff
(96.5 %id)
BX376851 Neuroblastoma Cot 50-normalized .l 146 to 1292 1 to 1133   tiling clone,   1133/1133
(100 %)
29 diff
(97.5 %id)
BE871649 adenocarcinoma, colon .l 146 to 939 1 to 778       778/879
(88 %)
25 diff
(97.2 %id)
BM557337 melanotic melanoma, skin .l 146 to 1190 17 to 1068   tiling clone,   1052/1069
(98 %)
52 diff
(95.2 %id)
BQ676240 melanotic melanoma, cell line, skin .l 146 to 997 10 to 873       863/943
(91 %)
36 diff
(96.2 %id)
CF141821 CNCAP(3)T-225 cell line, Prostate .l 151 to 587 8 to 444       437/444
(98 %)
5 diff
(98.9 %id)
BM802702 eye, retinoblastoma .l 151 to 1050 1 to 909       909/1133
(80 %)
32 diff
(97.2 %id)
TI_154172652   .l 151 to 748 80 to 677       598/600
(99 %)
8 diff
(98.7 %id)
BX437995 neuroblastoma .l 152 to 1037 1 to 883   tiling clone,   883/1028
(85 %)
22 diff
(97.9 %id)
BE545609 cervical carcinoma cell line, cervix .l 155 to 862 1 to 704       706/712
(99 %)
35 diff
(95.1 %id)
BI826274 brain, medulla .l 178 to 857 1 to 681       681/681
(100 %)
5 diff
(99.3 %id)
TI_57173357   .l 178 to 857 28 to 708       681/708
(96 %)
9 diff
(98.8 %id)
AA283814 ovarian tumor, ovary .l 256 to 699 1 to 443       443/443
(100 %)
1 diff
(99.8 %id)
CD634258   .l 260 to 870 1 to 610       610/612
(99 %)
6 diff
(99.1 %id)
CD634259   .l 260 to 673 1 to 415       413/415
(99 %)
9 diff
(97.9 %id)
CD634255   .l 262 to 750 155 to 645       491/498
(98 %)
18 diff
(96.4 %id)
AA283815 ovarian tumor, ovary .l 1204 to 1665 474 to 13   tiling clone, AAA   462/462
(100 %)
2 diff
(99.6 %id)
BE561887 Burkitt lymphoma, lymph .m 1 to 838 47 to 890 exact tiling clone,   846/891
(94 %)
52 diff
(94.2 %id)
BE396866 Burkitt lymphoma, lymph .m 9 to 612 1 to 604   tiling clone,   604/604
(100 %)
0 diff
(100 %id)
BE397166 Burkitt lymphoma, lymph .m 9 to 717 1 to 707   tiling clone,   707/722
(97 %)
7 diff
(99.1 %id)
TI_154163319   .m 626 to 1338 81 to 795   tiling clone,   715/717
(99 %)
36 diff
(95.0 %id)
TI_159701380   .m 646 to 1346 801 to 98   AAA   704/1004
(70 %)
5 diff
(99.6 %id)
TI_154097986   .m 661 to 1346 794 to 102   AAA   693/1142
(60 %)
44 diff
(96.2 %id)
TI_149289492   .m 662 to 1347 779 to 93   AAA   687/688
(99 %)
15 diff
(97.9 %id)
EC482242 Prostate .m 771 to 879 1 to 109       109/109
(100 %)
0 diff
(100 %id)
TI_154046439   .m 787 to 1347 658 to 99   AAA   560/907
(61 %)
29 diff
(96.9 %id)
BM796012 Ascites, stomach .m 881 to 1339 1 to 459       459/459
(100 %)
0 diff
(100 %id)
BG116614 duodenal adenocarcinoma, cell line, small intestine .m 928 to 1348 1 to 421   tiling clone,   421/438
(96 %)
1 diff
(99.8 %id)
Z39830 brain, total brain .m 1015 to 1347 333 to 1       333/333
(100 %)
0 diff
(100 %id)
EC505485 Prostate .m 1032 to 1136 1 to 101       101/101
(100 %)
4 diff
(96.1 %id)
EC448564 Prostate .m 1049 to 1151 1 to 99       99/99
(100 %)
4 diff
(96.0 %id)
BE535384 cervix .m 1050 to 1360 1 to 311   tiling clone, AAA   311/311
(100 %)
0 diff
(100 %id)
CN367061 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .m 1075 to 1347 1 to 273   AAA   273/273
(100 %)
0 diff
(100 %id)
T31405 colon, embryo .m 1084 to 1297 1 to 214       214/214
(100 %)
0 diff
(100 %id)
AW952417   .m 1085 to 1347 1 to 263   AAA   263/263
(100 %)
0 diff
(100 %id)
EC480432 Prostate .m 1129 to 1220 1 to 92       92/92
(100 %)
0 diff
(100 %id)
AA776558   .m 1140 to 1358 232 to 14   AAA   219/219
(100 %)
0 diff
(100 %id)
TI_149298994   .m 1229 to 1347 211 to 91   AAA   500/923
(54 %)
30 diff
(96.8 %id)
EC553036 Prostate .m 1237 to 1346 110 to 1       110/110
(100 %)
0 diff
(100 %id)
BE464995 carcinoid, lung .m 1237 to 1346 119 to 10       110/119
(92 %)
0 diff
(100 %id)
TI_159705986   .m 1241 to 1347 203 to 94   AAA   653/949
(68 %)
33 diff
(96.6 %id)
AI074491 brain, glioblastoma (pooled) .m 1263 to 1347 103 to 19   AAA   85/85
(100 %)
0 diff
(100 %id)
AI056229 liver and spleen .m 1263 to 1348 92 to 7       86/92
(93 %)
0 diff
(100 %id)
AI698434 uterus, well-differentiated endometrialadenocarcinoma, 7 pooled tumors .m 1263 to 1358 96 to 1       96/96
(100 %)
0 diff
(100 %id)
AI000909 breast .m 1269 to 1347 79 to 1       79/79
(100 %)
1 diff
(98.8 %id)
AI587472 adenocarcinoma, Pancreas .m 1271 to 1347 89 to 13   AAA   77/77
(100 %)
0 diff
(100 %id)
AI468941 lymph node, lymphoma, follicular mixed small and largecell .m 1272 to 1348 85 to 9       77/85
(90 %)
0 diff
(100 %id)
GD146165   .m 1274 to 1348 1 to 72       72/81
(88 %)
2 diff
(97.6 %id)
AI590731 brain, tumor, 5 pooled (see description) .m 1274 to 1347 74 to 1       74/74
(100 %)
0 diff
(100 %id)
BG482545 choriocarcinoma, placenta .n 1 to 911 1 to 907 K48T tiling clone,   907/928
(97 %)
29 diff
(96.9 %id)
BQ056595 lymph, lymphoma, cell line .n 334 to 1064 11 to 746   tiling clone,   735/1128
(65 %)
36 diff
(96.9 %id)
BQ890364 lymph, lymphoma, cell line .n 334 to 1136 12 to 832   tiling clone,   820/873
(93 %)
36 diff
(95.9 %id)
BG746996 adenocarcinoma cell line, colon .o 1 to 779 1 to 778 exact tiling clone,   778/946
(82 %)
11 diff
(98.9 %id)
BG746959 adenocarcinoma cell line, colon .o 1 to 873 1 to 868 V6F S7H P8H Y9I W10G ...     868/868
(100 %)
18 diff
(98.0 %id)
BG824338 adenocarcinoma cell line, colon .o 1 to 872 1 to 886 exact tiling clone,   886/886
(100 %)
18 diff
(98.0 %id)
BG821770 adenocarcinoma cell line, colon .o 1 to 920 1 to 912 V6F S7H P8H Y9I W10G ... tiling clone,   912/931
(97 %)
28 diff
(97.0 %id)
BQ065408 lymph, lymphoma, cell line .o 14 to 912 26 to 933   tiling clone,   907/997
(90 %)
29 diff
(97.1 %id)
BQ642619 lymph, lymphoma, cell line .p 1 to 897 1 to 900 exact tiling clone,   900/903
(99 %)
12 diff
(98.7 %id)
CF139233 CNCAP(3)T-225 cell line, Prostate .q 1 to 455 1 to 455 exact tiling clone,   455/455
(100 %)
5 diff
(99.0 %id)
TI_154169429   .q 7 to 738 90 to 821 exact tiling clone,   732/931
(78 %)
21 diff
(97.8 %id)
CD247712 embryonic stem cells, WA01, passage 38 .q 11 to 762 22 to 774 exact tiling clone,   753/886
(84 %)
23 diff
(97.5 %id)
BM459690 leiomyosarcoma, uterus .r 1 to 745 18 to 766 F18C tiling clone,   750/966
(77 %)
26 diff
(97.4 %id)
CV310348 colon .s-u 1 to 400 403 to 3 N6Y N9D H22P K32E Q36P ... tiling clone, Submitted on the opposite strand 401/403
(99 %)
0 diff
(100 %id)
BF950882 nervous_normal .s-u 155 to 657 6 to 510       505/511
(98 %)
9 diff
(98.3 %id)
BF953654 nervous_normal .s-u 155 to 668 26 to 539   tiling clone,   514/539
(95 %)
6 diff
(98.9 %id)
AW809257 stomach .s-u 251 to 538 1 to 287       287/287
(100 %)
7 diff
(97.6 %id)
BX363798   .t-u 1 to 412 1 to 416 exact tiling clone,   416/416
(100 %)
13 diff
(96.9 %id)
DW416085 Liver .u 1 to 293 17 to 310 T10N tiling clone,   298/310
(96 %)
16 diff
(94.9 %id)
BG024750 lymph, lymphoma, cell line Gene C19orf48andSNORD88CandSNORD88B, variant not shown         This clone was ignored    
TI_57234731   Gene C19orf48andSNORD88CandSNORD88B, variant not shown         Suspected internal deletion, this clone was ignored    
TI_154173185   Gene C19orf48andSNORD88CandSNORD88B, variant not shown         Suspected internal deletion, this clone was ignored    
TI_154185530   Gene C19orf48andSNORD88CandSNORD88B, variant not shown         This clone was ignored    
TI_151714172   Gene C19orf48andSNORD88CandSNORD88B, variant not shown       AAA Suspected internal deletion, this clone was ignored    
? Gene Summary Gene on genome mRNA:.a, .b, .c, .d, .e, .f, .g, .h, .i, .j, .k, .l, .m, .n, .o, .p, .q, .r, .s-u, .t-u, .u Alternative mRNAs features, proteins, introns, exons, sequences Expression Tissue Function, regulation, related genes D